CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.In Sub-studies 1 and 2...
Phase 1, Phase 2
Seattle, Washington, United States of America and 55 other locations
treating measurable residual disease in patients with acute myeloid leukemia. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzu...
Phase 2
Seattle, Washington, United States
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
Seattle, Washington, United States of America and 23 other locations
with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia...
Phase 3
Seattle, Washington, United States and 108 other locations
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (C...
Phase 1, Phase 2
Seattle, Washington, United States and 11 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Seattle, Washington, United States and 110 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....
Phase 1
Seattle, Washington, United States and 22 other locations
works in treating medically less-fit patients with acute myeloid leukemia or other high-grade myeloid neoplasms. Drugs used in chemotherapy,...
Phase 2
Seattle, Washington, United States
The study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia...
Phase 1, Phase 2
Seattle, Washington, United States and 42 other locations
This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN...
Phase 1, Phase 2
Seattle, Washington, United States of America and 28 other locations
Clinical trials
Research sites
Resources
Legal